Introduction – Esthesioneuroblastoma (ENB) is an uncommon, rapidly growing tumour that apparently originates from the roof of the nasal cavity or the olfactory fossa. It is otherwise referred to as "olfactory neuroblastoma" due to its neuroepithelium component. This tumour, when leaving the confines of the olfactory fossa, often involves the cribriform plate, skull base and the lymph nodes of the neck. These are commonly are treated with surgery and radiotherapy if they are in the early stage at initial presentation. Advanced tumours are treated multi–modally using chemotherapy, radiotherapy and surgery. It is imperative that patients undergo early biopsy of nasal mass on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) to establish prompt diagnosis. Here, we are describing a case series of ENB from the Dept. of ENT – Head & Neck Surgery, with different modes of presentation, course of disease, outcomes, prognostic factors and quality–of–life (QOL) measures.

Objectives – To compare Quality–of–Life measures in patients diagnosed with olfactory neuroblastoma and to study survival functions

Methods – Prospective cohort comparative study. Duration – 7 years (from 2011 – 2018).  Data collected from the hospital tumour board registry and by questionnaire.

Results – Recorded data shows poor Quality of Life soon after diagnosis. Same worsened if the presenting stage was advanced. Survival statistics calculated.

Conclusion – Case series data from our tertiary care centre was compared with other similar studies and certain merits and demerits are highlighted. Esthesioneuroblastoma, though rare, has great effect on QOL of the patient and his/her care–givers / relatives. Early detection and radio–imaging, avoidance of risk factors go a long way in making life better in those diagnosed with such malignant pathology. Further palliative measures, combination treatment options have to be explored to definitely improve QOL.